StockData
Compass Therapeutics, Inc. logo

Compass Therapeutics, Inc. (CMPX) stock

CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$0.61−0.05 (-8.28%)

Close on Nov 17, 2026Market cap $109.26MP/E –Yield –

Compass Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Compass Therapeutics

Compass Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Compass Therapeutics figures

See a number that looks wrong?